Research programme: CNS disorder therapeutics - Saniona

Drug Profile

Research programme: CNS disorder therapeutics - Saniona

Latest Information Update: 16 Dec 2015

Price : $50

At a glance

  • Originator Saniona
  • Developer Pfizer; Saniona
  • Class Small molecules
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - CNS disorders

Highest Development Phases

  • Preclinical CNS disorders

Most Recent Events

  • 16 Sep 2015 Preclinical trials in CNS disorders in Denmark (unspecified route) prior to September 2015
  • 16 Sep 2015 Research programme: CNS disorder therapeutics - Saniona is available for licensing as of 16 Sep 2015.
  • 16 Sep 2015 Pfizer terminates its licence for CNS disorder therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top